Sleep · 2004
Hypnotic efficacy of zaleplon for daytime sleep in rested individuals.
Клиническое исследованиеКонтролируемое клиническое исследованиеСтатьяПоддержка правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Whitmore Jeffrey N, Fischer Joseph R, Storm William F
Аннотация
STUDY OBJECTIVES: The primary objective of this study was to determine whether zaleplon (10 mg) effectively promoted sleep during the daytime in well-rested individuals when compared to placebo. A secondary objective was to see if, while not expected, the use of zaleplon impacted the performance of well-rested individuals upon awakening.
DESIGN: Repeated measures with 2 within-subject factors: drug (placebo/zaleplon) and trial (hourly testing during waking hours). Polysomnographic variables were recorded during a 3.5-hour nap following drug administration. Performance measures and subjective reports were collected during every waking trial of each session.
SETTING: The study was conducted at the Chronobiology and Sleep Laboratory located at Brooks Air Force Base.
PARTICIPANTS: Twelve participants, 6 men and 6 women.
INTERVENTIONS: 10-mg zaleplon or placebo capsules, single afternoon dose. Drug administration was counterbalanced and double-blinded.
MEASUREMENTS AND RESULTS: Zaleplon allowed participants to obtain significantly more slow-wave sleep than under placebo. There was also a trend for participants under zaleplon to accomplish a greater amount of sleep than under placebo. Performance was not adversely impacted following a 3.5-hour daytime sleep under zaleplon, nor were any undesirable symptoms induced.
CONCLUSIONS: Zaleplon improves sleep quality when used by rested individuals to accomplish daytime sleep.
DESIGN: Repeated measures with 2 within-subject factors: drug (placebo/zaleplon) and trial (hourly testing during waking hours). Polysomnographic variables were recorded during a 3.5-hour nap following drug administration. Performance measures and subjective reports were collected during every waking trial of each session.
SETTING: The study was conducted at the Chronobiology and Sleep Laboratory located at Brooks Air Force Base.
PARTICIPANTS: Twelve participants, 6 men and 6 women.
INTERVENTIONS: 10-mg zaleplon or placebo capsules, single afternoon dose. Drug administration was counterbalanced and double-blinded.
MEASUREMENTS AND RESULTS: Zaleplon allowed participants to obtain significantly more slow-wave sleep than under placebo. There was also a trend for participants under zaleplon to accomplish a greater amount of sleep than under placebo. Performance was not adversely impacted following a 3.5-hour daytime sleep under zaleplon, nor were any undesirable symptoms induced.
CONCLUSIONS: Zaleplon improves sleep quality when used by rested individuals to accomplish daytime sleep.